We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Iq-ai Limited | LSE:IQAI | London | Ordinary Share | JE00BD4H0R42 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.55 | 1.50 | 1.60 | 1.55 | 1.55 | 1.55 | 113,265 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Florists | 536k | -512k | -0.0028 | -5.54 | 2.83M |
TIDMIQAI
RNS Number : 9880A
IQ-AI Limited
27 January 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
IQ-AI's Subsidiary Imaging Biometrics Adds to Development Team
IQ-AI is pleased to announce its subsidiary, Imaging Biometrics, LLC (IB), has enlisted the services of Jay Urbain, PhD to its software development team. Dr. Urbain brings significant experience in machine learning, deep learning, and data science, with significant contributions across multiple industrial applications including healthcare.
Dr. Urbain started his career at Marquette Medical Systems (now part of GE Healthcare) and for the past 16 years held the position of professor at the Milwaukee School of Engineering where he developed and taught courses in artificial intelligence and general computer science topics. As an nVidia Certified Deep Learning Instructor, Dr. Urbain conducts deep learning workshops in collaboration with nVidia and his research passion is at the intersection of machine learning and healthcare. He remains an adjunct professor at the Milwaukee School of Engineering as well as at the Medical College of Wisconsin.
Michael Schmainda, non-executive director of IQ-AI, said, "We are very excited that Dr. Urbain has joined IB's development team. His background and expertise dovetail perfectly with IB's existing team of software engineers, and will catalyze the development of new technologies and products".
The Directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited Trevor Brown/Vinod Kaushal/Qu Li Tel: 020 7469 0930 ---------------------------------------------------------- Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: 020 7220 9797 ----------------------------------------------------------
About IQ-AI Ltd
IQ-AI, Ltd, the parent company of StoneChecker(R) and Imaging Biometrics(R), is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
STRGCGDBUDDDGGR
(END) Dow Jones Newswires
January 27, 2020 04:29 ET (09:29 GMT)
1 Year Iq-ai Chart |
1 Month Iq-ai Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions